Lantana: Lantana camara (Verbenaceae)

peer reviewe

Genetic variability, chemotype distribution, and aggressiveness of Fusarium culmorum on durum wheat in Tunisia

Fusarium culmorum is the most commonly reported root rot pathogen in Tunisian durum wheat. Isolates of the pathogen from four durum wheat growing areas in the north of Tunisia were analyzed for their chemotypes. Two chemotypes were detected at unequal abundance (96% of 3-ADON and 4% of NIV). Distribution of a SNP mutation located at the position 34 bp after the first exon of the EF-1\u3b1 partial sequence was analysed, to verify whether the haplotype was specifically associated to Fusarium root rot. A and T haplotypes were homogeneously distributed in three different Tunisian regions (Mateur, Beja and Bousalem) but not for the region of Bizerte, from which greatest number of A haplotype strains were detected. The isolates were tested for their virulence under glasshouse conditions, and a mean of 91% of crown and root infection was observed. Chemotype influenced virulence, but there was no significant influence of the geographical origin or haplotype on virulence. The distribution of three inter simple sequence repeats (ISSR) was examined, to better understand the structure of F. culmorum populations in Tunisia. A total of 27 fragments were obtained with eight polymorphic bands. Cluster analysis showed a high level of similarity between isolates. Analysis of molecular variance confirmed that there was little genetic differentiation among F. culmorum strains from different locations

Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs

To compare venlafaxine and selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram) in the treatment of depression. Meta-analysis of 34 randomized, double-blind studies identified by a worldwide search of all research sponsored by Wyeth Pharmaceuticals through January 2007. Patients were treated with venlafaxine ( n = 4191; mean dose 151 mg/day) or SSRIs ( n = 3621); nine studies also included a placebo control group ( n = 932). The primary outcome measure was intent-to-treat (ITT) remission rates (Hamilton Rating Scale for Depression ≤7) at week 8. The overall difference in ITT remission rates was 5.9% favoring venlafaxine (95% confidence interval [CI]: .038–.081; p < .001). Based on this difference, the number needed to treat (NNT) to benefit is 17 (95% CI: 12–26). In the nine placebo controlled studies, the drug-placebo differences were 6% (.02–.09) for the SSRIs and 13% (.09–.16) for venlafaxine. For the specific SSRIs, the difference versus fluoxetine (mean dose = 37 mg/day; 20 studies) was significant (6.6% [95% CI: .030–.095]); smaller differences versus paroxetine (mean dose = 25 mg/day; eight studies; 5%), sertraline (mean dose = 127 mg/day; three studies; 3%), and citalopram (mean dose = 38 mg/day; two studies; 4%) were not significant. Attrition rates due to adverse events were higher with venlafaxine than with SSRI therapy, 11% and 9% respectively ( p = .0011). These results indicate that venlafaxine therapy is statistically superior to SSRIs as a class, but only to fluoxetine individually. The clinical significance of this modest advantage seems limited for the broad grouping of major depressive disorder. Nonetheless, an NNT of 17 may be of public health relevance given the large number of patients treated for depression and the significant burden of illness associated with this disorder